A survey of exposure to the use of Xiaflex for the treatment of Peyronie's disease among United States urology residency programs
© 2023. The Author(s), under exclusive licence to Springer Nature Limited..
Xiaflex® (collagenase clostridium histolyticum) is a Food and Drug Administration-approved treatment for patients with Peyronie's disease. Despite its approval and implementation, there is concern that urologists in training are offered minimal exposure to its use. Thus, the purpose of this study was to evaluate the exposure of urology residents to Peyronie's disease and its management, particularly Xiaflex®. A Google Forms survey regarding the exposure of residents to Peyronie's disease and use of Xiaflex® was created and disseminated through email to urology programs. Overall, 47 institutional responses were received. At 45 institutions (95.7%), residents receive training in directly evaluating and caring for patients with Peyronie's disease. At 46 institutions (97.9%), residents receive training in observing and/or performing surgical procedures for Peyronie's disease. Residents at 31 institutions (66.0%) receive observational or procedural training for non-surgical management of Peyronie's disease, specifically Xiaflex®. Residents receive non-surgical training from an academic faculty who is fellowship trained in sexual medicine at 25 institutions and an academic faculty not trained in sexual medicine at six institutions. There exists a glaring disparity in residency exposure to Xiaflex®. Further research is warranted to elucidate how programs can provide residents with further exposure to the use of Xiaflex® in patients with Peyronie's disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
International journal of impotence research - 36(2024), 2 vom: 02. März, Seite 155-159 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Loloi, Justin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 20.03.2024 Date Revised 23.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41443-023-00781-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363580417 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363580417 | ||
| 003 | DE-627 | ||
| 005 | 20240323234719.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41443-023-00781-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1342.xml |
| 035 | |a (DE-627)NLM363580417 | ||
| 035 | |a (NLM)37865716 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Loloi, Justin |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A survey of exposure to the use of Xiaflex for the treatment of Peyronie's disease among United States urology residency programs |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2024 | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a Xiaflex® (collagenase clostridium histolyticum) is a Food and Drug Administration-approved treatment for patients with Peyronie's disease. Despite its approval and implementation, there is concern that urologists in training are offered minimal exposure to its use. Thus, the purpose of this study was to evaluate the exposure of urology residents to Peyronie's disease and its management, particularly Xiaflex®. A Google Forms survey regarding the exposure of residents to Peyronie's disease and use of Xiaflex® was created and disseminated through email to urology programs. Overall, 47 institutional responses were received. At 45 institutions (95.7%), residents receive training in directly evaluating and caring for patients with Peyronie's disease. At 46 institutions (97.9%), residents receive training in observing and/or performing surgical procedures for Peyronie's disease. Residents at 31 institutions (66.0%) receive observational or procedural training for non-surgical management of Peyronie's disease, specifically Xiaflex®. Residents receive non-surgical training from an academic faculty who is fellowship trained in sexual medicine at 25 institutions and an academic faculty not trained in sexual medicine at six institutions. There exists a glaring disparity in residency exposure to Xiaflex®. Further research is warranted to elucidate how programs can provide residents with further exposure to the use of Xiaflex® in patients with Peyronie's disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Microbial Collagenase |2 NLM | |
| 650 | 7 | |a EC 3.4.24.3 |2 NLM | |
| 700 | 1 | |a Schuppe, Kyle |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, Raghuram V |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Farah |e verfasserin |4 aut | |
| 700 | 1 | |a Bernstein, Ari |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, Pritika |e verfasserin |4 aut | |
| 700 | 1 | |a Kulkarni, Nikhil |e verfasserin |4 aut | |
| 700 | 1 | |a Masterson, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Ramasamy, Ranjith |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of impotence research |d 1992 |g 36(2024), 2 vom: 02. März, Seite 155-159 |w (DE-627)NLM074730967 |x 1476-5489 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2024 |g number:2 |g day:02 |g month:03 |g pages:155-159 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41443-023-00781-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2024 |e 2 |b 02 |c 03 |h 155-159 | ||